Drug intelligence / Profile preview

methylene blue + SonoVue

Development stage: Unknown
Lead developer: China-Japan Friendship Hospital
Modality: Small Molecules
Administration: Intradermal, Subcutaneous, Peritumoral

Overview

A dual-modality contrast agent combining methylene blue dye and SonoVue (sulfur hexafluoride microbubbles) used for sentinel lymph node detection in breast cancer patients. The combination allows for both visual identification through methylene blue staining and ultrasound-based detection through contrast enhancement. Studies show this combination achieves a 100% identification rate of sentinel lymph nodes while potentially reducing the total number of lymph nodes removed during surgery compared to methylene blue alone, which may lead to reduced surgical trauma and postoperative complications.

Other names: CEUS with methylene bluemethylene blue microbubblesMB2MB-2MB 2

Targets

MAOA (Monoamine oxidase A)

Beyond the preview

Go deeper on methylene blue + SonoVue.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methylene blue + SonoVue.

Explore the full profile